References
- Ghebre‐Sellassie I. Pellets: a general overview. Pharmaceutical Pelletization Technology, I. Ghebre‐Sellassie. Marcel Dekker, New York 1989; 1–13
- Ghebre‐Sellassie I., Knoch A. Pelletization techniques. Encyclopedia of Pharmaceutical Technology2nd Ed., J. Swarbrick, J. C. Boylan. Marcel Dekker, Inc, New York 2002; Vol 3: 2067–2080
- Dashevsky A., Kolter K., Bodmeier R. Compression of pellets coated with various polymer dispersions. Int. J. Pharm. 2004; 279: 19–26
- Holm P., Bonde M., Wigmore T. Pelletization by granulation in a roto‐processor RP‐2. Part I: effects of process and product variables on granule growth. Pharm. Technol. Eur. 1996; 8(8)21–36
- Holm P. Pelletization by granulation in a roto‐processor RP‐2. Part II: effects of process and product variables on agglomerates shape and porosity. Pharm. Technol. Eur. 1996; 10(10)38–45
- Maggi L., Bonfanti A., Santi P., Massimo G., Catellani P. L., Bellotti A., Colombo P., Zanchetta A. The suitable of a small scale high‐shear mixer for powder pelletization. Pharm. Technol. Eur. 1996; 10(10)82–90
- Bianchini R., Bruni G., Gazzaniga A., Vecchio C. Influence of extrusion‐spheronization processing on the physical properties of d‐indobufen pellets containing pH adjusters. Proceeding of 10th Pharmaceutical Technology Conference. Solid dosage Research Unit, LiverpoolUK 1991; 577–592
- Gazzaniga A., Sangalli M. E., Rillosi M., Bruni G., Vecchio C., Giordano F. Cyclodextrin as pelletization agent in the extrusion‐spheronization process: drug. Dev. Ind. Pharm. 1998; 24(9)869–873
- Stella J. V., Rajewski R. A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 1997; 14(5)556–567
- Zecchi V., Orienti I., Fini A. Control of NSAID dissolution by β‐cyclodextrin complexation. Pharm. Acta Helv. 1988; 63(11)299–302
- Loftsson T., Olafsdottir B. J., Frioriksdottir H., Jonsdottir S. Cyclodextrin complexation of NSAIDs: physicochemical characteristics. Eur. J. Pharm. Sci. 1993; 1: 95–101
- Bettinetti G. P., Manderioli A., Faucci M. T., Bramanti G., Sorrenti M. Interactions of ketoprofen and ibuprofen with β‐cyclodextrins in solution and in the solid state. Int. J. Pharm. 1998; 166(2)189–203
- He Z., Zhang T., Tang X., Chen X., Zhang R., Song Z. Utilization of b‐cyclodextrin and 2‐hydroxypropyl‐β‐cyclodextrin as solubilizers of ibuprofen. Shenyang Yaoke Daxue Xuebao 1998; 15(4)235–237
- Loftsson T., Sigurdsson H. H., Masson M., Schipper N. Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs. Pharmazie 2004; 59(1)25–29
- Chow D. D., Karara A. H. Characterization, dissolution and bioavailability in rats of ibuprofen‐β‐cyclodextrin complex system. Int. J. Pharm. 1986; 28: 95–101
- Martin A. Micromeritics. Physical Pharmacy4th Ed. Lea & Fabinger, Philadelphia 1993; 423–452
- Fernandez‐Hervas M. J., Holgado M. A., Rabasco A. M., Fini A. Use of fractal geometry on the characterization of particles morphology: application to the diclofenac hydroxyethylpirrolidone salt. Int. J. Pharm. 1994; 108: 187–194
- Holgado M. A., Fernandez‐Hervas M. J., Alvarez‐Fuentes J., Vela M. T., Rabasco A. M., Fini A. Characterization of modified paracetamol by means of SEM and fractal analysis. Int. J. Pharm. 1996; 142: 143–151
- European Pharmacopeia. Directorate for the Quality of Medicines of Council of Europe, StrasbourgFrance 2001; 200–201
- Claudy P., Germain P., Letoffe J. M., Bayol A., Gonzalez B. Étude thermodynamique de la réaction d'hydratation de la β–cyclodextrine. Thermochim. Acta 1990; 161: 75–84